Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule
ApprovedActive 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Medullary Thyroid Cancer
Conditions
Medullary Thyroid Cancer
Trial Timeline
Feb 25, 2015 → Jan 1, 2035
NCT ID
NCT01896479About Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule
Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule is a approved stage product being developed by Exelixis for Medullary Thyroid Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT01896479. Target conditions include Medullary Thyroid Cancer.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01896479 | Approved | Active |
Competing Products
9 competing products in Medullary Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selpercatinib + Cabozantinib + Vandetanib | Eli Lilly | Phase 3 | 77 |
| Selpercatinib | Eli Lilly | Phase 1/2 | 41 |
| Pralsetinib + Cabozantinib + Vandetanib | Roche | Phase 3 | 77 |
| • TF2 and 68 Ga-IMP-288 | Gilead Sciences | Phase 1/2 | 40 |
| Caprelsa | Sanofi | Pre-clinical | 22 |
| Vandetanib 300mg | Sanofi | Phase 1/2 | 40 |
| Vandetanib | Sanofi | Phase 3 | 76 |
| vandetanib + omeprazole + ranitidine | Sanofi | Phase 1 | 32 |
| cabozantinib | Exelixis | Pre-clinical | 20 |